作者: Tong Chen , Yi Mou , Jiani Tan , Linlin Wei , Yixue Qiao
DOI: 10.1016/J.INTIMP.2015.01.011
关键词: Cytokine 、 Lung injury 、 Lung 、 Pathogenesis 、 In vivo 、 Lipopolysaccharide 、 Pharmacology 、 Immunology 、 Dexamethasone 、 Protein kinase B 、 Medicine
摘要: CDDO-Me, initiated in a phase II clinical trial, is a potential useful therapeutic agent for cancer and inflammatory dysfunctions, whereas the therapeutic efficacy of CDDO-Me on LPS-…